Abstract:Estela Noguera-Ortega 1,2 , Steven M. Albelda 1,2 1 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 2 Pulmonary and Critical Care Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Comment on: Zhang Y, Tacheva-Grigorova SK, Sutton J, et al . Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res 2023;29:971-85. Keywords: Small cell lung cancer (SCLC); chimeric antigen receptor T cells (CAR T cells); delta-like ligand-3 (DLL3) Submitted Jan 03, 2024. Accepted for publication Feb 19, 2024. Published online Apr 24, 2024. doi: 10.21037/tlcr-24-10 Although great successes have been achieved treating leukemias, lymphoma, and multiple myeloma using chimeric antigen receptor T (CAR T) cells, resulting in multiple regulatory agency approvals, reports showing efficacy in solid tumors are much fewer. To date, some promising results have been seen in neuroblastoma (1) and gastro intestinal (GI) tumors (2), but lung cancer, and specifically small cell lung cancer (SCLC) has not been successfully treated. This is unfortunate, as successful treatments for this deathly cancer remain very limited. There are many postulated reasons for this lack of success in solid tumor. Key limitations include: (I) lack of highly specific targets for the CAR T cells, (II) poorly functioning T cells that produce suboptimal CAR T cells, (III) poor trafficking of the CAR T cells into tumors, (IV) tumor heterogeneity, (V) poor persistence of the cells, and (VI) rapid development of CAR T cell hypofunction. SCLC presents some additional challenges as the disease is often extensive and rapidly progressive requiring rapid preparation of the CAR T cells [reviewed in (3)]. A recent paper by Zhang et al. entitled "Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer" (4) describes a sophisticated, multipronged approach for SCLC that can serve as an example for the development of CAR T cells. The authors have elected to address some of these important solid tumor CAR T cell challenges by using allogeneic T cells. Off-the-shelf CAR T cell approaches provide a ready-to-use clinical product that can be derived from cells from young healthy donors in large scale, avoiding delays, cutting costs (by eliminating the need for a personalized product for each patient) and generating a consistent, highly effective cell therapy product (5,6). However, allogenic CAR T cell products have a number of potential issues. By using T cells from a different donor to generate CAR T cells and infusing them into the cancer patient, foreign cells are being transplanted into the donor. This results in the host immune system potentially rejecting the infused product—via host versus graft (HvG) rejection, but also, since the transplanted cells are T cells, these cells can also mount an immune response against the host, resulting in graft versus host disease (GvHD) (7). Zhang and collaborators approach these two potential limitations by using a previously described gene-editing methodology—Transcriptional Activator-Like Effector Nuclease (TALEN) to knockout genes to avoid each problem. To limit GvHD, they "knock out" the T-cell receptor α constant (TRAC) locus that encodes for the T cell receptor of the infused CAR T cells making them non-reactive against the host cells (4). Of note, other investigators have successfully used this strategy, knocking out the TRAC loci and at the same time inserting the CAR into the same locus, where it results in more uniform expression and prevents tonic signaling (8). Similar approaches are currently being evaluated in clinical trials (4,7). To enhance engraftment, CAR T cell persistence, and diminish HvG rejection, this group used lymphodepletion/immunosuppression using a pan-T cell anti-CD52 antibody. However, to prevent the CAR T cells from also being depleted by the antibody, they genetically modified the T cells using TALENs to remove CD52. This strategy was found to be effective in clinical trials (9). Both of these approaches are being developed by Allogene Therapeutics for use in other CAR T cells targeting CD19, BCMA, and CD70. An alternative approach, used by others to prevent HvG rejection, has been to knock down the beta2 microglobulin gene which prevents the surface expression of human leukocyte antigen (HLA) molecules on the surface of the T cells (10). Although this prevents them from being recognized by endogenous CD8 T cells, it does make more susceptible to NK cell mediated attack (11). The main focus of the manuscript is to validate a SCLC target called delta-like ligand-3 (DLL3) and to optimize CAR T cells expressing D -Abstract Truncated-

TREM1/DAP12 based novel multiple chain CAR‐T cells targeting DLL3 show robust anti‐tumour efficacy for small cell lung cancer

CAR NK‐92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth

DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy

Small cell, big promises: targeting small cell lung cancer with CAR T cells

TREM1/Dap12-based CAR-T cells show potent antitumor activity.

Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer

Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions

DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models

Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer

Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: an Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial

Abstract 5550: QLS31904: An anti-DLL3/CD3 bispecific antibody for T cell immunotherapy of small cell lung cancer

Abstract 1872: A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models

Abstract 3146: HRA00130-C004, a novel anti-DLL3 ADC with bystander effect, high DAR and favorable safety profiles

A theranostic approach: Imaging and therapy of delta-like ligand 3–expressing small cell lung cancers.

Abstract 6716: DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 costimulation for the treatment of DLL3-expressing cancers

Bispecific CD19-CD20 and CD19-CD22 CAR-T Cells with Glycogen Synthase Kinase (GSK)-3β Inhibitor TWS119 Treatment Have Superior Therapeutic Effects on Mantle Cell Lymphoma

Abstract 2364: Anti-CADM1 chimeric antigen receptor (CAR) is a novel therapeutic strategy against small cell lung cancer

Current Status and Progress of CAR-T Cell Therapy in the Treatment of Small Cell Lung Cancer

SC134-TCB targeting fucosyl-GM1, a T cell engaging antibody with potent anti-tumour activity in preclinical small-cell lung cancer models

Abstract LB282: Therapeutic efficacy and dosimetry for a 177-lutetium radiolabeled minibody targeting DLL3 in a preclinical model of small cell lung cancer